iShares Genomics Immunology and Healthcare ETF IDNA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +63.27%
- 1 year
- +69.62%
- Open
- 42.89
- Prev close
- 42.99
- Mkt cap
- 201.57M
- Vol
- 291.18K
- Avg vol
- 140.84K
- EPS
- 1.56
- P/E
- 27.48
- Div yield
- 0.00%
More statistics
- Low
- 42.30
- High
- 43.75
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 24.11
- 200-d avg
- 23.98
News
2 months ago benzinga.com
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive…
2 months ago benzinga.com
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
2 months ago zacks.com
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
2 months ago seekingalpha.com
IDNA: 3 Catalysts To Watch Closely
IDNA jumped 13.53% in one day on 2.8x average volume after three catalysts, including Moderna's and Merck's positive Phase 3 INTerpath-001 data. IDNA trades at a 14.90x forward P/E, implying a 6.7%…
2 months ago benzinga.com
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
9 months ago defenseworld.net
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Up 428.3% in January
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short…
1 year ago benzinga.com
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.
1 year ago benzinga.com
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.
1 year ago seekingalpha.com
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value…
1 year ago benzinga.com
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald…
1 year ago benzinga.com
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
1 year ago etftrends.com
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical…
-
2 years ago benzinga.com
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
2 years ago seekingalpha.com
IDNA: Healthcare Dashboard For February
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks…
2 years ago etftrends.com
Disruptive Tech Theme of the Week: 7 Disruptive Themes for 2024
To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.
2 years ago etftrends.com
VettaFi Voices On: Accessing Disruptive Innovation
Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.
3 years ago seekingalpha.com
IDNA: Continues To Underperform, But With Long-Term Potential
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has…
3 years ago seekingalpha.com
IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to…
3 years ago etftrends.com
Thematic Index Lineup Joins VettaFi and the Future Is Bright
A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of products and minimal assets. However, at the end…
-
3 years ago benzinga.com
Move Over, ChatGPT: 5 Stock Ideas For Leveraging The Power Of AI In Health Care, Cybersecurity
Generative artificial intelligence has taken the world by storm in 2023.
3 years ago investorplace.com
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
3 years ago seekingalpha.com
IDNA: Healthcare Dashboard For February
Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality.
3 years ago zacks.com
Will 2023 be the Year of Cathie Wood ETFs?
Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.
3 years ago seekingalpha.com
Can Health Care Stocks Outperform Again In 2023?
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
3 years ago seekingalpha.com
IDNA: Healthcare Dashboard For November
The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same…
4 years ago etf.com
BlackRock Zeros in on Themed ETFs
The category represents a rapidly growing portion of the issuer's lineup.
4 years ago seekingalpha.com
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in…
4 years ago investorplace.com
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as…